Elisabetta Patorno, MD, DrPH

Brigham and Women's Hospital
Boston, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• 1A-04 - Comparative Effectiveness of Current Glucose-Lowering Medications in Type 2 Diabetes Mellitus: Emulation of a modified GRADE trial

  Sunday, August 24, 2025
  11:15 AM - 11:30 AM ET

• SW-1D - What are possible approaches when the active comparator new users design (ACNU) is not easily applicable?

  Sunday, August 24, 2025
  1:30 PM - 3:00 PM ET

• 3A-01 - Cardiovascular Effectiveness of Semaglutide: Using Real-World Data to Predict Findings of the Ongoing SOUL Cardiovascular Outcomes Trial

  Monday, August 25, 2025
  8:15 AM - 8:30 AM ET

• 3B - Keep pumping: cardiovascular and respiratory drug safety

  Monday, August 25, 2025
  8:15 AM - 9:45 AM ET

• 4E-05 - A data mining application tool to detect safety signals of sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease.

  Monday, August 25, 2025
  5:15 PM - 5:30 PM ET

• 5E - The safety dance: drugs for obesity and metabolic disorders

  Tuesday, August 26, 2025
  8:30 AM - 10:00 AM ET

• 5E-06 - Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in patients with Type 2 Diabetes

  Tuesday, August 26, 2025
  9:45 AM - 10:00 AM ET

• 5F-06 - Randomized clinical trial replication and second-stage study to evaluate the risk of serious infections in biological drug users with psoriatic arthritis/psoriasis using the Italian VALORE distributed database network

  Tuesday, August 26, 2025
  9:45 AM - 10:00 AM ET

• 6C-03 - Using Real-World Data to Predict Findings of an Ongoing Phase IV Trial: Glycemic Control of Semaglutide vs Standard of Care

  Tuesday, August 26, 2025
  2:00 PM - 2:15 PM ET